One year ago today, Bob Hugin’s company Celgene paid $280 million to settle a whistleblower suit over defrauding taxpayers and marketing cancer drugs for unapproved uses.
“Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs”
– New York Times, July 25, 2017
“The Celgene settlement is the latest in a string of multimillion-dollar fines that pharmaceutical companies have paid to settle charges that they inappropriately marketed certain drugs in recent years, but this case is one of the largest settlements to involve a cancer drug, said Reuben A. Guttman, who represented the whistle-blower, Beverly Brown.
“Cancer drugs are seen as more difficult to pursue in so-called off-label marketing cases in part because oncologists often prescribe drugs for unapproved uses in an effort to combat a deadly and still mysterious disease.”